Tulisokibart (MK-7240/PRA023)

MK-7240/PRA023 · Prometheus Biosciences, a subsidiary of Merck & Co.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tulisokibart (MK-7240/PRA023), covering 2024-06-27 to 2024-06-27. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) [Phase 2]

See pricing